Search Results

• • 24 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Response to Bradley

  Author:ANDREAS PFUTZNERFrom:Diabetes Care (Vol. 22, Issue 10) Peer-Reviewed

  Oct. 1999320 words Brief article We appreciate the comments by C. Bradley [1] that, in fact, indicate an error in the presentation of our data in a recently published article [2]. By mistake, a less reliable part of the analyzed data was given, while...

• Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects

  Authors:Andreas Pfutzner, Christian A Schneider, and Thomas ForstFrom:Expert Review of Cardiovascular Therapy (Vol. 4, Issue 4) Peer-Reviewed

  July 200611,633 words Report Author(s): Andreas Pfützner 1 , Christian A Schneider 2 , Thomas Forst 3 Keywords: cardiovascular disease; insulin resistance; pioglitazone; thiazolidinediones; Type 2 diabetes mellitus According to recent...

• Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults

  Authors:Silke Meyer, Stephan Schaefer, Lisette Stolk, Pascal Arp, Andre G Uitterlinden, Ursula Plockinger, et al.From:Pharmacogenomics (Vol. 10, Issue 10) Peer-Reviewed

  Oct. 20096,573 words Clinical report 1550LAuthor(s): Silke Meyer [[dagger]] 1 , Stephan Schaefer 2 , Lisette Stolk 3 , Pascal Arp 4 , André G Uitterlinden 5 , Ursula Plöckinger 6 , Günter K Stalla 7 , Ulrich Tuschy 8 , Matthias M Weber 9 , Alexander Weise 10 ,...

• Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients

  Authors:KLAUS RAVE, TIM HEISE, ANDREAS PFUTZNER, LUTZ HEINEMANN, and PETER T. SAWICKIFrom:Diabetes Care (Vol. 24, Issue 5) Peer-Reviewed

  May 20013,775 words Article KLAUS RAVE [1] TIM HEISE [1] ANDREAS PFUTZNER [2] LUTZ HEINEMANN [2] PETER T. SAWICKI [3] OBJECTIVE -- To quantify pharmacokinetic and pharmacodynamic properties of regular insulin and insulin lispro in...

• Severe insulin resistance treated with insulin lispro

  Authors:Helmut R. Henrichs, Heinz Unger, Michael E. Trautmann, and Andreas PfutznerFrom:The Lancet (Vol. 348, Issue 9036) Peer-Reviewed

  Nov. 2, 199640 words Article

   Abstract Only

• Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes

  Authors:Thomas Forst, Andreas Pfutzner, Frank Flacke, Alan Krasner, Cloth Hohberg, Eda Tarakci, et al.From:Diabetes Care (Vol. 33, Issue 1) Peer-Reviewed

  Jan. 20103,893 words Article 1540LOBJECTIVE--Recent studies suggested an impact of prandial insulin delivery on postprandial regulation of tissue blood flow. This study compared the effect of VIAject with human regular insulin and insulin lispro on...

• Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms

  Authors:Silke Meyer, Stephan Schaefer, Diana Ivan, Lisette Stolk, Pascal Arp, Andre G Uitterlinden, et al.From:Pharmacogenomics (Vol. 10, Issue 2) Peer-Reviewed

  Feb. 20096,137 words Report 1410LAuthor(s): Silke Meyer [[dagger]] 1 , Stephan Schaefer 1 , Diana Ivan 1 , Lisette Stolk 2 , Pascal Arp 2 , André G Uitterlinden 2 , Peter P Nawroth 3 , Ursula Plöckinger 4 , Günter K Stalla 5 , Ulrich Tuschy 6 ,...

• Effect of insulin glulisine on microvascular blood flow and endothelial function in the postprandial state

  Authors:Clothilde Hohberg, Thomas Forst, Martin Larbig, Michael Safinowski, Stefan Diessel, Silvia Hehenwarter, et al.From:Diabetes Care (Vol. 31, Issue 5) Peer-Reviewed

  May 20083,357 words Clinical report 1540LOBJECTIVE--To investigate the effect of insulin glulisine on postprandial microvascular blood flow in type 2 diabetes. RESEARCH DESIGN AND METHODS--A total of 15 patients with type 2 diabetes received insulin...

• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

  Authors:Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, et al.From:The Lancet (Vol. 394, Issue 10193) Peer-Reviewed

  July 13, 20193,935 words Article

   Abstract Only

• FlexPen.sup.[R] for the delivery of insulin: accuracy, injection force and patient preference

  Author:Andreas PfutznerFrom:Expert Review of Medical Devices (Vol. 6, Issue 2) Peer-Reviewed

  Mar. 20096,589 words Article Author(s): Andreas Pfützner 1 Keywords: diabetes; dose accuracy; FlexPen® ; insulin; Next Generation FlexPen® In patients with Type 1 or 2 diabetes, insulin is generally delivered via injection with vial and...

• Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes

  Authors:Andreas Pfutzner, Thomas Kunt, Cloth Hohberg, Agnes Mondok, Sabine Pahler, Thomas Konrad, et al.From:Diabetes Care (Vol. 27, Issue 3) Peer-Reviewed

  Mar. 20043,558 words Article OBJECTIVE--In later stages of type 2 diabetes, proinsulin and proinsulin-like molecules are secreted in increasing amounts with insulin. A recently introduced chemiluminescence assay is able to detect the uncleaved...

• Coverage of postprandial blood glucose excursions with inhaled Technosphere Insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes

  Authors:Klaus Rave, Tim Heise, Andreas Pfutzner, and Anders H. BossFrom:Diabetes Care (Vol. 30, Issue 9) Peer-Reviewed

  Sept. 20071,212 words Clinical report 1430LTechnosphere Insulin (TI) is a formulation of regular human insulin (RHI) that provides efficient pulmonary administration (1) and demonstrates unique pharmacokinetic and pharmacodynamic properties compared with...

• Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus

  Authors:Thomas Forst and Andreas PfutznerFrom:Expert Review of Endocrinology & Metabolism (Vol. 8, Issue 1) Peer-Reviewed

  Jan. 201311,682 words Article 1520LAuthor(s): Thomas Forst [*] 2 , Andreas Pfützner 1 Keywords : dipeptidyl peptidase-4 inhibitor; linagliptin; Type 2 diabetes mellitus A recent report of the International Diabetes Federation estimates that...

• Elevated Peripheral Visfatin Levels in Narcoleptic Patients

  Authors:Norbert Dahmen, Nina Manderscheid, Jana Helfrich, Petra B. Musholt, Thomas Forst, Andreas Pfutzner, et al.From:PLoS ONE (Vol. 3, Issue 8) Peer-Reviewed

  Aug. 20, 20083,792 words Article 1390LObjective Narcolepsy is a severe sleep disorder that is characterized by excessive daytime sleepiness, cataplexies and a tendency towards obesity. Recent discoveries indicate that the major pathophysiology is a loss...

• Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment

  Authors:James H. Anderson, Jr., Rocco L. Brunelle, Veikko A. Koivisto, Andreas Pfutzner, Michael E. Trautmann, Louis Vignati, et al.From:Diabetes (Vol. 46, Issue 2) Peer-Reviewed

  Feb. 19974,701 words Article Insulin lispro, an insulin analog recently developed particularly for mealtime therapy, has a fast absorption rate and a short duration of action. We compared insulin lispro and regular human insulin in the mealtime...

• Additive effect of GHRd3 and COLIA1 polymorphisms on the GH-substitution dose in GH-deficient adults

  Authors:Silke Hartleb, Ursula Plockinger, Gunter K Stalla, Ulrich Tuschy, Matthias M Weber, Andreas Pfutzner, et al.From:Pharmacogenomics (Vol. 12, Issue 12) Peer-Reviewed

  Dec. 20115,832 words Report 1380LAuthor(s): Silke Hartleb 1 , Ursula Plöckinger 2 , Günter K Stalla 3 , Ulrich Tuschy 4 , Matthias M Weber 5 , Andreas Pfützner 6 , Peter Herbert Kann [**] 7 KEYWORDS : collagen; collagen type I [alpha] 1;...

• Inhaled Technosphere/Insulin Shows a Low Variability in Metabolic Action in Type 2 Diabetic Patients

  Authors:ANDREAS PFUTZNER, TIM HEISE, SOLOMON STEINER, LUTZ HEINEMANN, and KLAUS RAVEFrom:Diabetes (Vol. 49, Issue 5) Peer-Reviewed

  May 2000314 words Article Although the variability of insulin action is of major importance for diabetes therapy, only few studies have addressed this topic. In diabetic patients, the variability of inhaled insulin preparations has not yet been...

• Results of a Dose-Response Study with a New Pulmonary Insulin Formulation and Inhaler

  Authors:KLAUS M. RAVE, TIM HEISE, ANDREAS PFUTZNER, SOLOMON STEINER, and LUTZ HEINEMANNFrom:Diabetes (Vol. 49, Issue 5) Peer-Reviewed

  May 2000291 words Brief article Technosphere is a new drug delivery system, facilitating absorption of peptides and proteins by the pulmonary route. Technosphere/Insulin (TI) is an ordered lattice array of Technosphere and recombinant human insulin...

• Association of COLIA1 Sp1 polymorphism with the effect of subcutaneously injected recombinant hGH in GH-deficient adults

  Authors:Silke Meyer, Marlitt Haist, Stephan Schaefer, Diana Ivan, Jochen R Ittner, Peter P Nawroth, et al.From:Pharmacogenomics (Vol. 9, Issue 8) Peer-Reviewed

  Aug. 20085,945 words Clinical report 1460LAuthor(s): Silke Meyer [[dagger]] 1 , Marlitt Haist 1 , Stephan Schaefer 1 , Diana Ivan 1 , Jochen R Ittner 2 , Peter P Nawroth 3 , Ursula Plöckinger 4 , Günter K Stalla 5 , Ulrich Tuschy 6 , Matthias M Weber 7 ,...

• Bioavailibility and Pharmacokinetic Properties of Inhaled Dry Powder Technosphere/Insulin

  Authors:SOLOMON STEINER, KLAUS RAVE, TIM HEISE, OLIVER HARZER, FRANK FLACKE, ANDREAS PFUTZNER, et al.From:Diabetes (Vol. 49, Issue 5) Peer-Reviewed

  May 2000247 words Brief article Technosphere/Insulin (TI) is a new drug delivery system for pulmonary administration, which was designed to achieve transport of regular human insulin through the intact respiratory endothelium into the systemic...